The Combination Therapy of Hypertension to Prevent Cardiovascular Events (COPE) trial: Rationale and design

Toshio Ogihara, Masunori Matsuzaki, Hiroaki Matsuoka, Kazuaki Shimamoto, Kazuyuki Shimada, Hiromi Rakugi, Seiji Umemoto, Akira Kamiya, Norihiro Suzuki, Hiroo Kumagai, Yasuo Ohashi, Shuichi Takishita, Keishi Abe, Takao Saruta, K. Kikuchi, S. Itoh, H. Suzuki, T. Fujita, J. Higaki, T. EtohC. Tei, S. Nogawa, T. Yoshikawa, K. Yumura, K. Utsunomiya, K. Kario, K. Kitagawa, H. Makino, M. Matsumoto, K. Hayashi, M. Kawana, M. Fujishima, K. Otsuka, K. Tanabe

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

A number of major clinical trials have demonstrated the clinical benefits of lowering blood pressure and have indicated that a majority of patients with hypertension will require more than one drug to achieve optimal blood pressure control. However, there is little data showing which antihypertensive combination best protects patients from cardiovascular events and which best achieves the target blood pressure with the fewest adverse events. The Combination Therapy of Hypertension to Prevent Cardiovascular Events (COPE) trial is the first large-scale investigator-initiated multicenter study with a prospective, randomized, open, blinded endpoint evaluation (PROBE) design to directly compare cardiovascular mortality and morbidity, incidence of adverse drug reaction, and degree of blood pressure reduction in Japanese hypertensive patients for a combination of angiotensin receptor blockers, β-blockers or thiazide diuretics in addition to a calcium antagonist, benidipine hydrochloride, with a response-dependent dose titration scheme. The COPE trial is being conducted with the cooperation of more than 100 centers and clinics in Japan and involves 3,000 patients, who will be followed for 3 years. Eligible patients are being enrolled from May 2003 until May 2006. Results from the COPE trial should provide new evidence for selecting optimal combination therapies for hypertensive patients.

Original languageEnglish
Pages (from-to)331-338
Number of pages8
JournalHypertension Research
Volume28
Issue number4
DOIs
Publication statusPublished - 2005 Apr 1

Keywords

  • Benidipine
  • Combination therapy
  • Hypertension
  • Multicenter clinical trial
  • PROBE (prospestive, randomized, open, blinded endpoint evaluation)

ASJC Scopus subject areas

  • Internal Medicine
  • Physiology
  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'The Combination Therapy of Hypertension to Prevent Cardiovascular Events (COPE) trial: Rationale and design'. Together they form a unique fingerprint.

  • Cite this

    Ogihara, T., Matsuzaki, M., Matsuoka, H., Shimamoto, K., Shimada, K., Rakugi, H., Umemoto, S., Kamiya, A., Suzuki, N., Kumagai, H., Ohashi, Y., Takishita, S., Abe, K., Saruta, T., Kikuchi, K., Itoh, S., Suzuki, H., Fujita, T., Higaki, J., ... Tanabe, K. (2005). The Combination Therapy of Hypertension to Prevent Cardiovascular Events (COPE) trial: Rationale and design. Hypertension Research, 28(4), 331-338. https://doi.org/10.1291/hypres.28.331